Inpharma

Pyrimethamine/sulfadoxine still a good bet for malaria prevention
pp. 1-1(1)

Amlodipine/perindopril + atorvastatin on form in hypertension
pp. 2-2(1)

Self-reported influenza virus vaccination and pneumococcal vaccination status is reasonably accurate
pp. 3-3(1)

Rotavirus vaccine poor value for kids
pp. 3-3(1)

Male circumcision a kinder cut in HIV prevention
pp. 3-3(1)

Egg donor compensation appropriate in the US
pp. 3-3(1)

US hep A vaccination programme successful
pp. 4-4(1)

China's universal infant hep B vaccination: progress report
pp. 4-4(1)

Indometacin of value for preventing IVH in preterm infants
pp. 4-4(1)

Ambrisentan: ARIES results are a good sign for PAH
pp. 5-6(2)

Theophylline appears to effective for oesophageal (noncardiac) chest pain
pp. 6-6(1)

Ubidecarenone [coenzyme Q10] enhances interferon-α-2b therapy after surgery in patients with malignant melanoma
pp. 6-6(1)

Traxoprodil [CP 101606] may be beneficial for patients with treatment resistant depression
pp. 6-6(1)

R&D News from EULAR
pp. 7-7(1)

PRX 00023, a long-acting 5-HT1A agonist, may not be effective for anxiety but shows promise for depression
pp. 7-7(1)

News from the Annual Meeting of the American Psychiatric Association
pp. 8-9(2)

Ivermectin effective for onchocerciasis but resistance emerging
pp. 9-9(1)

Systemic therapies against invasive candidiasis
pp. 10-10(1)

News from DDW
pp. 10-10(1)

Bevacizumab a new weapon in the fight against renal cancer
pp. 11-12(2)

News from ESH
pp. 12-12(1)

Cetuximab first line in mCRC: benefits CRYSTAL clear
pp. 13-14(2)

SSRIs in conjunction with cognitive behavioural therapy (CBT), compared with an SSRI alone, do not improve outcomes for children and adolescents with moderate-to-severe depression
pp. 14-14(1)

Agalsidase-β [Fabrazyme] has demonstrated long term efficacy in the treatment of patients with Fabry's disease
pp. 14-14(1)

Bevacizumab AVAiLs in non-small cell lung cancer
pp. 15-16(2)

Diethylcarbamazine vs ivermectin mass administration for lymphatic filariasis
pp. 16-16(1)

Women who obtain the majority of their daily calcium from their diet have higher bone density than those who obtain it from supplements
pp. 16-16(1)

Nebulised formoterol: a breath of fresh air for COPD
pp. 17-18(2)

Still the status quo for painful diabetic neuropathy
pp. 18-18(1)

Colecalciferol [vitamin D3] or ergocalciferol [vitamin D2] only confer a reduction in the risk of hip fracture when used in combination with calcium
pp. 18-18(1)

Nitazoxanide is effective for the treatment of patients with metronidazole-resistant Clostridium difficile-associated colitis
pp. 18-18(1)

Fentanyl pharmacokinetics are altered in patients with major burns
pp. 19-19(1)

Irbesartan vs atenolol: effects on vascular structure, BP
pp. 19-19(1)

Telmisartan is more effective than valsartan for proteinuria in patients with hypertension associated with metabolic syndrome
pp. 19-19(1)

Cholinesterase inhibitors reduce cortical β-amyloid deposition in patients with dementia with Lewy bodies
pp. 19-19(1)

In patients with long-term alcoholism, propofol may potentially be preferable to isoflurane for anaesthesia during surgery
pp. 19-19(1)

Call for change in the Avandia aftermath
pp. 20-20(1)

Are functional erythropoietin receptors present in cancer cells?
pp. 20-20(1)

Lower GI event rates similar for etoricoxib, diclofenac
pp. 20-20(1)

Merck's RotaTeq undergoes label revision
pp. 21-21(1)

GSK reports link between Ventolin and MI
pp. 21-21(1)

New Avastin safety info issued in Canada
pp. 21-21(1)

Lumiracoxib [Prexige] appears to have significantly less impact on BP than ibuprofen in patients with osteoarthritis who also have controlled hypertension
pp. 21-21(1)

EU product approvals
pp. 22-22(1)

US product approvals
pp. 22-22(1)

Product approvals in Canada
pp. 22-22(1)

Product launches in Japan
pp. 22-22(1)

US product launches
pp. 22-22(1)

Neurim Pharmaceuticals have announced that the Committee for Medicinal Products in Human use of the EMEA has issued an approval recommendation for prolonged-release melatonin 2mg [Circadin].
pp. 22-22(1)

Other US regulatory news
pp. 23-23(1)

Eisai has announced the launch of rufinamide [Inovelon] in Germany as an adjunct therapy for Lennox-Gastaut Syndrome.
pp. 23-23(1)